Iron chelation therapy for myelodysplastic syndrome: If and when

Mayo Clinic Proceedings

Volumn 81, Issue 2, 2006, Pages 197-198

  Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; LENALIDOMIDE;

ERYTHROCYTE TRANSFUSION; HUMAN; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NOTE; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RISK BENEFIT ANALYSIS;

EID: 32144438546     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.2.197     Document Type: Note

References (19)

1. FDA News. FDA approves first oral drug for chronic iron overload. November 9, 2005. Available at: www.fda.gov/bbs/topics/news/2005/NEW01258.HTML. Accessibility verified December 23, 2005.
2. Olivieri NF. Adherence to deferoxamine therapy: heeding Hippocrates and Osler [editorial]. Am J Hematol. 2004;76:415-416.
3. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597-1602.
4. Cappellini MD, Cohen A, Piga A, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2005 [Epub ahead of print].
5. Rund D, Rachmilewitz E. β-Thalassemia. N Engl J Med. 2005;353:1135-1146.
6. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary [letter]. Blood. 2002;99:3074-3075.
7. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis- associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med. 1998;129:946-953.
8. Milman N, Pedersen P, a Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol. 2001;80:737-744.
9. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta-thalassemia syndromes: a decade of progress. Am J Med. 2005;118: 957-967.
10. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104:34-39.
11. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.
12. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood). 2005;24:67-78.
13. Germing U, Strupp C, Kuendgen A, et al. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol. 2006;132:162-167.
14. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood. 1998;91:1100]. Blood. 1997;89:2079-2088.
15. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
16. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037-1046.
17. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
18. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94:288-299.
19. Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1:153-158.